Article Abstract

Can we use interleukin-1β blockade for lung cancer treatment?

Authors: Adrian Gottschlich, Stefan Endres, Sebastian Kobold


Over the last decade the field of immunotherapy has grown to be one of the most promising fields in oncology. Targeted therapies using monoclonal antibodies, kinase inhibitors or T cell therapies emerged to be an important part of cancer treatment regimens and their impact is growing (1). However, all successful clinical therapies and clinical trials focused on the treatment of pre-existing symptomatic cancers while strategies preventing cancer development or symptomatic outgrowth have remained the holy grail of cancer care.